CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.

导出原文传递

翻译打印收藏纠错

作者： Yi,Liu ^[1] ; Sanmei,Wang ^[2] ; Maria-Luisa,Schubert ^[1] ; Annika,Lauk ^[3] ; Hao,Yao ^[1] ; Maximilian Felix,Blank ^[1] ; Chunhong,Cui ^[1] ; Maike,Janssen ^[1] ; Christina,Schmidt ^[1] ; Stefanie,Göllner ^[4] ; Christian,Kleist ^[1] ; Fengbiao,Zhou ^[1] ; Jens-Ulrich,Rahfeld ^[1] ; Tim,Sauer ^[5] ; Michael,Schmitt ^[1] ; Carsten,Müller-Tidow ^[6]

作者单位： Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany. ^[1] Molecular Medicine Partnership Unit (MMPU), European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital, Heidelberg, Germany. ^[2] Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China. ^[3] Shanghai University of Medicine and Health Sciences, Shanghai, China. ^[4] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. ^[5] Fraunhofer Institute for Cell Therapy and Immunology IZI, Halle, Germany. ^[6]

关键词 CD33 CD33-editing CRISPR/Cas9 acute myeloid leukemia chimeric antigen receptor T cells gemtuzumab ozogamicin hematopoietic stem and progenitor cells third generation CAR T cells

主题词造血干细胞移植(Hematopoietic Stem Cell Transplantation);造血干细胞(Hematopoietic Stem Cells);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);白血病, 髓样, 急性(Leukemia, Myeloid, Acute)

DOI 10.1002/ijc.33865

PMID 34766343

发布时间 2022-02-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交